Aptima

Aptima (Hologic) swabs were transported on ice and stored at 4°C for <30 days until testing by the Aptima Combo 2 for chlamydia and gonorrhea, by Aptima TV for trichomonas, and by Aptima MG for Mycoplasma genitalium.

Anonymized blood samples were collected at the Virology laboratory, Toulouse University Hospital before the first Delta variant infections appeared and were biobanked at the hospital Biological Resource Center (certified to NF 596-900 standards). This study was approved by the French Research Ethics Committee Est-111 (COVID BioToul ID-RCB 2020-AO1292-37; ClinicalTrials.gov registration number NCT04385108).
To ensure consistency of the kinetics of the immune response, we used blood samples collected 1 to 3 months postinfection among the nonvaccinated (19 (link)) and 1 month after the last injection among the vaccinated HCWs. Blood samples from unvaccinated health care workers (n = 162) who had an infection documented by nucleic acid testing of a nasopharyngeal sample (Aptima; Hologic, USA) (26 (link)) were collected in July 2020, i.e., 1 to 3 months postinfection in this cohort (27 (link)). Samples were collected from vaccinated health care workers (n = 263) at the antibody peak following vaccination, i.e., 1 month after the last injection. A total of 217 vaccinated health care workers (HCWs) were seronegative for SARS-CoV-2 prior to vaccination. Of these, 105 (48.4%) were vaccinated with BNT162b2/BNT162b2, 94 (43.3%) with ChAdOx1-S/BNT162b2, and 18 (8.3%) with ChAdOx1-S/ChAdOx1-S. The remaining 46 HCWs were seropositive for SARS-CoV-2 prevaccination and were all given BNT162b2.

Anonymized blood samples were collected at the Virology laboratory, Toulouse University Hospital before the first Delta variant infections appeared and were biobanked at the hospital Biological Resource Center (certified to NF 596-900 standards). This study was approved by the French Research Ethics Committee Est-111 (COVID BioToul ID-RCB 2020-AO1292-37; ClinicalTrials.gov registration number NCT04385108).
To ensure consistency of the kinetics of the immune response, we used blood samples collected 1 to 3 months postinfection among the nonvaccinated (19 (link)) and 1 month after the last injection among the vaccinated HCWs. Blood samples from unvaccinated health care workers (n = 162) who had an infection documented by nucleic acid testing of a nasopharyngeal sample (Aptima; Hologic, USA) (26 (link)) were collected in July 2020, i.e., 1 to 3 months postinfection in this cohort (27 (link)). Samples were collected from vaccinated health care workers (n = 263) at the antibody peak following vaccination, i.e., 1 month after the last injection. A total of 217 vaccinated health care workers (HCWs) were seronegative for SARS-CoV-2 prior to vaccination. Of these, 105 (48.4%) were vaccinated with BNT162b2/BNT162b2, 94 (43.3%) with ChAdOx1-S/BNT162b2, and 18 (8.3%) with ChAdOx1-S/ChAdOx1-S. The remaining 46 HCWs were seropositive for SARS-CoV-2 prevaccination and were all given BNT162b2.

The self-collected penile-meatal swabs were eluted in phosphate-buffered saline (PBS), frozen, and together with paired, frozen, urine samples sent to the Johns Hopkins University for additional testing. Two hundred microliters of the swab elution was placed in the multitest swab transport medium (STM). Urine samples (≈2 mL) were transferred to urine specimen transport tubes per manufacturer’s instructions. Swab and urine samples were tested for M. genitalium as well as Neisseria gonorrhoeae, Chlamydia trachomatis, and Trichomonas vaginalis using the Aptima (Hologic, San Diego, CA, USA) M. genitalium transcription-mediated amplification-based Research Use Only, Combo 2 C. trachomatis/N. gonorrhoeae, and T. vaginalis assays, respectively. Samples with invalid Aptima C. trachomatis, N. gonorrhoeae, T. vaginalis, or M. genitalium results were retested; samples with repeated (tested twice) invalid Aptima results were excluded from the analysis.